L-Tryptophan
|
Basic information |
| Metabolite name | L-Tryptophan |
 | HMDB0000929 |
 |
C00078 |
 |
6305 |
| Synonyms | Tryptophane; |
| No. of studies | 144 |
|
Basic information |
| Metabolite name | L-Tryptophan |
| HMDB0000929 |
|
C00078 |
|
6305 |
| Synonyms | Tryptophane; |
| No. of studies | 144 |
|
Relationship between L-Tryptophan and depression (count: 144) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M002 | Type1 | CUMS group vs. control group | Cerebral cortex | Sprague-Dawley rat | Up |
| Study M002 | Type1 | CUMS group vs. control group | Thalamus | Sprague-Dawley rat | Up |
| Study M003 | Type1 | day 27 CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M005 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M008 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M009 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M009 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M009 | Type2 | CUMS + middle dose of Xiaoyaosan group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M009 | Type2 | CUMS + venlafaxine group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M009 | Type2 | CUMS + high dose of Xiaoyaosan group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M018 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M024 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M024 | Type2 | CUMS + venlafaxine group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M024 | Type2 | CUMS + fluoxetine group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M033 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Down |
| Study M037 | Type2 | sertraline treatment group four-week vs. baseline | Serum | Human | Up |
| Study M042 | Type3 | fluoxetine group vs. control group | Cerebrospinal fluid | Rhesus monkey | Down |
| Study M046 | Type1 | LPS group vs. control group | Dorsal hippocampus | C57BL/6N mouse | Up |
| Study M046 | Type1 | LPS group vs. control group | Nucleus accumbens | C57BL/6N mouse | Up |
| Study M046 | Type1 | LPS group vs. control group | Central amygdala | C57BL/6N mouse | Up |
| Study M048 | Type1 | CVS group vs. control group | Serum | Wistar rat | Down |
| Study M048 | Type2 | CVS + CSGS group vs. CVS group | Serum | Wistar rat | Up |
| Study M048 | Type2 | CVS + fluoxetine group vs. CVS group | Serum | Wistar rat | Up |
| Study M061 | Type1 | depressed group vs. control group | Plasma | Human | Down |
| Study M068 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M069 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M072 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M072 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M076 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M076 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M076 | Type2 | CUMS + Anemarrhena saponins and Lilium saponins group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M079 | Type1 | acute LPS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M087 | Type2 | esketamine group 2-h vs. baseline | Plasma | Human | Down |
| Study M095 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M096 | Type1 | CUMS group vs. control group | Hippocampus | Wistar rat | Down |
| Study M096 | Type1 | CUMS group vs. control group | Plasma | Wistar rat | Down |
| Study M096 | Type1 | CUMS group vs. control group | Prefrontal cortex | Wistar rat | Down |
| Study M096 | Type2 | CUMS + paroxetine group vs. CUMS group | Plasma | Wistar rat | Up |
| Study M096 | Type2 | CUMS + paroxetine group vs. CUMS group | Hippocampus | Wistar rat | Up |
| Study M096 | Type2 | CUMS + paroxetine group vs. CUMS group | Prefrontal cortex | Wistar rat | Up |
| Study M1004 | Type2 | CUMS + Zhi-Zi-Chi decoctions group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M1004 | Type2 | CUMS + Zhi-Zi-Chi decoctions group vs. CUMS group | Ileum | Sprague-Dawley rat | Up |
| Study M1005 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1005 | Type1 | CUMS group vs. control group | Ileum | Sprague-Dawley rat | Down |
| Study M1005 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M1005 | Type2 | CUMS + butyrate group vs. CUMS group | Ileum | Sprague-Dawley rat | Up |
| Study M1005 | Type2 | CUMS + butyrate group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M1005 | Type2 | CUMS + fluoxetine group vs. CUMS group | Ileum | Sprague-Dawley rat | Up |
| Study M1005 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M1005 | Type2 | CUMS + butyrate group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1005 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1008 | Type2 | CCFM1025 group vs. placebo group | Faece | Human | Up |
| Study M1015 | Type1 | lipopolysaccharide group vs. control group | Cortex | C57BL/6J mouse | Up |
| Study M1015 | Type1 | lipopolysaccharide group vs. control group | Hippocampus | C57BL/6J mouse | Up |
| Study M1015 | Type2 | lipopolysaccharide + amitriptyline group vs. lipopolysaccharide group | Cortex | C57BL/6J mouse | Down |
| Study M1015 | Type2 | lipopolysaccharide + high dose of soy isoflavones group vs. lipopolysaccharide group | Cortex | C57BL/6J mouse | Down |
| Study M1015 | Type2 | lipopolysaccharide + high dose of soy isoflavones group vs. lipopolysaccharide group | Hippocampus | C57BL/6J mouse | Down |
| Study M1015 | Type2 | lipopolysaccharide + low dose of soy isoflavones group vs. lipopolysaccharide group | Cortex | C57BL/6J mouse | Down |
| Study M1015 | Type2 | lipopolysaccharide + middle dose of soy isoflavones group vs. lipopolysaccharide group | Cortex | C57BL/6J mouse | Down |
| Study M1015 | Type2 | lipopolysaccharide + middle dose of soy isoflavones group vs. lipopolysaccharide group | Hippocampus | C57BL/6J mouse | Down |
| Study M1015 | Type2 | lipopolysaccharide + amitriptyline group vs. lipopolysaccharide group | Hippocampus | C57BL/6J mouse | Down |
| Study M1015 | Type2 | lipopolysaccharide + low dose of soy isoflavones group vs. lipopolysaccharide group | Hippocampus | C57BL/6J mouse | Down |
| Study M1024 | Type1 | CUMS group vs. control group | CA3 region of hippocampus | ICR mouse | Down |
| Study M1024 | Type1 | CUMS group vs. control group | CA1 region of hippocampus | ICR mouse | Down |
| Study M1024 | Type1 | CUMS group vs. control group | DG region of hippocampus | ICR mouse | Down |
| Study M1025 | Type2 | CUMS + Bacillus licheniformis group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M1033 | Type1 | small intestinal bacterial overgrowth and chronic constipation group vs. control group | Urine | Human | Down |
| Study M1033 | Type2 | small intestinal bacterial overgrowth and chronic constipation group, after rifaximin treatment vs. baseline | Urine | Human | Up |
| Study M1033 | Type2 | small intestinal bacterial overgrowth and chronic diarrhea group, after rifaximin treatment vs. baseline | Urine | Human | Up |
| Study M1039 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M1039 | Type2 | CUMS + high dose of Angelicae Sinensis Radix group vs. CUMS group | Liver | Sprague-Dawley rat | Up |
| Study M1039 | Type2 | CUMS + low dose of Angelicae Sinensis Radix group vs. CUMS group | Liver | Sprague-Dawley rat | Up |
| Study M104 | Type2 | CUMS + fluoxetine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M1054 | Type1 | CUMS group vs. control group | Plasma | ICR mouse | Down |
| Study M1054 | Type2 | CUMS + ChaihuYujinxiang granules group vs. CUMS group | Plasma | ICR mouse | Up |
| Study M1059 | Type1 | CRS group vs. control group | Colon | Wistar rat | Up |
| Study M1059 | Type1 | CRS group vs. control group | Serum | Wistar rat | Down |
| Study M1059 | Type1 | CRS group vs. control group | Cortex | Wistar rat | Down |
| Study M1059 | Type1 | CRS group vs. control group | Striatum | Wistar rat | Down |
| Study M1059 | Type1 | CRS group vs. control group | Hippocampus | Wistar rat | Down |
| Study M1063 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M1071 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M1075 | Type1 | CSDS group vs. control group | Serum | C57BL/6J mouse | Down |
| Study M1081 | Type1 | CUMS group vs. control group | Brain | C57BL/6 J mouse | Down |
| Study M1081 | Type1 | CUMS group vs. control group | Colon | C57BL/6 J mouse | Down |
| Study M1081 | Type1 | CUMS group vs. control group | Serum | C57BL/6 J mouse | Down |
| Study M1081 | Type2 | CUMS + 1-methyl-tryptophan group vs. CUMS group | Serum | C57BL/6 J mouse | Up |
| Study M1081 | Type2 | CUMS + 1-methyl-tryptophan group vs. CUMS group | Colon | C57BL/6 J mouse | Up |
| Study M1081 | Type2 | CUMS + 1-methyl-tryptophan group vs. CUMS group | Brain | C57BL/6 J mouse | Up |
| Study M1081 | Type3 | 1-methyl-tryptophan group vs. control group | Serum | C57BL/6 J mouse | Up |
| Study M1081 | Type3 | 1-methyl-tryptophan group vs. control group | Brain | C57BL/6 J mouse | Up |
| Study M1081 | Type3 | 1-methyl-tryptophan group vs. control group | Colon | C57BL/6 J mouse | Up |
| Study M1082 | Type1 | interferon gamma group vs. control group | Serum | C57BL/6 J mouse | Down |
| Study M1082 | Type1 | interferon gamma group vs. control group | Colon | C57BL/6 J mouse | Down |
| Study M1082 | Type2 | interferon gamma + Pulsatilla chinensis saponins group vs. interferon gamma group | Serum | C57BL/6 J mouse | Up |
| Study M1082 | Type2 | interferon gamma + 1-methyl-tryptophan group vs. interferon gamma group | Serum | C57BL/6 J mouse | Up |
| Study M1082 | Type2 | interferon gamma + 1-methyl-tryptophan group vs. interferon gamma group | Colon | C57BL/6 J mouse | Up |
| Study M1082 | Type2 | interferon gamma + Pulsatilla chinensis saponins group vs. interferon gamma group | Colon | C57BL/6 J mouse | Up |
| Study M1083 | Type1 | CUMS group vs. control group | Brain | C57BL/6 J mouse | Up |
| Study M1083 | Type1 | CUMS group vs. control group | Colon | C57BL/6 J mouse | Up |
| Study M1083 | Type1 | CUMS group vs. control group | Serum | C57BL/6 J mouse | Down |
| Study M1083 | Type2 | CUMS + Pulsatilla chinensis saponins group vs. CUMS group | Serum | C57BL/6 J mouse | Up |
| Study M1083 | Type2 | CUMS + Pulsatilla chinensis saponins group vs. CUMS group | Colon | C57BL/6 J mouse | Down |
| Study M1083 | Type2 | CUMS + Pulsatilla chinensis saponins group vs. CUMS group | Brain | C57BL/6 J mouse | Down |
| Study M1084 | Type1 | CUMS group vs. control group | Serum | C57BL/6 J mouse | Down |
| Study M1084 | Type1 | CUMS group vs. control group | Brain | C57BL/6 J mouse | Up |
| Study M1084 | Type1 | CUMS group vs. control group | Colon | C57BL/6 J mouse | Up |
| Study M1084 | Type2 | CUMS + Mesalazine group vs. CUMS group | Brain | C57BL/6 J mouse | Down |
| Study M1084 | Type2 | CUMS + Mesalazine group vs. CUMS group | Colon | C57BL/6 J mouse | Down |
| Study M1084 | Type2 | CUMS + Mesalazine group vs. CUMS group | Serum | C57BL/6 J mouse | Up |
| Study M1087 | Type1 | CSDS group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M1091 | Type1 | CMS vulnerable group vs. control group | Ventral hippocampus | Wistar rat | Up |
| Study M1092 | Type1 | CMS group vs. control group | Ventral hippocampus | Wistar rat | Up |
| Study M1093 | Type1 | CSDS group vs. control group | Serum | C57BL/6N mouse | Down |
| Study M1093 | Type1 | CSDS group vs. control group | Hippocampus | C57BL/6N mouse | Down |
| Study M1095 | Type1 | CUMS group vs. control group | Faece | ICR mouse | Down |
| Study M1095 | Type2 | CUMS + matrine group vs. CUMS group | Faece | ICR mouse | Up |
| Study M1098 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1098 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M1098 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1098 | Type2 | CUMS + L-theanine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M1098 | Type2 | CUMS + L-theanine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1098 | Type3 | L-theanine group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1102 | Type1 | nitenpyram group vs. control group, male offspring | Faece | ICR mouse | Down |
| Study M1102 | Type1 | nitenpyram group vs. control group, female offspring | Faece | ICR mouse | Down |
| Study M1107 | Type1 | CRS + FMT of adolescent depression group vs. CRS + FMT of healthy controls group | Colon | C57/6 J mouse | Down |
| Study M1108 | Type2 | CRS + Roseburia Intestinalis. group vs. CRS group | Prefrontal cortex | C57/6 J mouse | Up |
| Study M1129 | Type1 | high dose of perfluorooctane sulfonate group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M1129 | Type1 | middle dose of perfluorooctane sulfonate group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M1138 | Type2 | unpredictable subchronic stress + imipramine group vs. unpredictable subchronic stress group | Hippocampus | Swiss mouse | Down |
| Study M120 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M121 | Type1 | depressed group vs. control group | Plasma | Human | Down |
| Study M126 | Type1 | LPS group vs. control group | Brain | CD-1 mouse | Up |
| Study M134 | Type1 | CRS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M134 | Type2 | CRS + BH group vs. CRS group | Urine | Sprague-Dawley rat | Up |
| Study M136 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M136 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M136 | Type2 | CUMS + high dose of ZZHPD group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M137 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M137 | Type2 | CUMS + hypericin group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M137 | Type2 | CUMS + venlafaxine group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M147 | Type3 | SD acute vortioxetine group vs. SD acute control group | Plasma | Sprague-Dawley rat | Down |
| Study M150 | Type1 | IFN-alpha group vs. control group | Frontal cortex | Sprague-Dawley rat | Down |
| Study M150 | Type1 | IFN-alpha group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M163 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M171 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M171 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M171 | Type2 | CUMS + DXS group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M175 | Type2 | ECT treatment depressed group post-treatment vs. baseline | Plasma | Human | Down |
| Study M178 | Type1 | depressed group vs. control group | Serum | Human | Down |
| Study M204 | Type1 | LPS group vs. control group | Hypothalamus | CD-1 mouse | Down |
| Study M208 | Type1 | GCI model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M454 | Type1 | vascular depression model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M454 | Type2 | vascular depression model + YXST group vs. vascular depression model group | Hippocampus | ICR mouse | Up |
| Study M457 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M459 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M470 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M483 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M489 | Type1 | depression group vs. control group | Serum | Human | Down |
| Study M493 | Type1 | depression group vs. control group | Serum | Human | Down |
| Study M512 | Type1 | CUMS group vs. control group | Plasma | Goto-Kakizaki rat | Down |
| Study M513 | Type1 | male MDD group vs. male HC group | Serum | Human | Down |
| Study M522 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M522 | Type2 | CUMS + NaP group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M523 | Type1 | CUMS group vs. control group | Brain | Wistar rat | Down |
| Study M524 | Type1 | hydrocortisone group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M529 | Type1 | depressive symptom group vs. control group | Plasma | Human | Down |
| Study M539 | Type1 | LPS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M540 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M541 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M541 | Type2 | CUMS + low dose of AS group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M541 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M541 | Type2 | CUMS + high dose of AS group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M542 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M542 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M555 | Type1 | FMT group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M569 | Type2 | LPS + HPF group vs. LPS group | Serum | ICR mouse | Down |
| Study M570 | Type1 | CMS group vs. control group | Cerebral cortex | BALB/c mouse | Down |
| Study M571 | Type1 | LPS group vs. control group | Hypothalamus | CD-1 mouse | Down |
| Study M581 | Type2 | CUMS + fluoxetine group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M581 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M581 | Type2 | CUMS + high dose of S. chinensis group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M582 | Type3 | control + fluoxetine group vs. control group | Serum | C57BL/6N mouse | Down |
| Study M583 | Type1 | PSD group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M583 | Type2 | PSD group, after vs. before fluoxetine treatment | Hippocampus | Sprague-Dawley rat | Up |
| Study M592 | Type1 | CUMS group vs. control group, LC-MS | Liver | Sprague-Dawley rat | Up |
| Study M592 | Type2 | CUMS + low dose of XYS group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Down |
| Study M592 | Type2 | CUMS + high dose of XYS group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Down |
| Study M592 | Type2 | CUMS + venlafaxine group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Down |
| Study M593 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M593 | Type2 | CUMS + venlafaxine group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M593 | Type2 | CUMS + low dose of Radix Bupleuri-Radix Paeoniae Alba herb pair group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M593 | Type2 | CUMS + high dose of Radix Bupleuri-Radix Paeoniae Alba herb pair group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M596 | Type1 | elderly depression group vs. elderly control group | Urine | Human | Down |
| Study M602 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M611 | Type1 | LPS group vs. control group | Serum | Sprague-Dawley rat | Unknown |
| Study M619 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M627 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M629 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M629 | Type2 | CUMS + venlafaxine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M629 | Type2 | CUMS + middle dose of coumaroylspermidine extract group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M630 | Type2 | acupuncture + antidepressant group, post vs. before treatment | Urine | Human | Up |
| Study M632 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Unknown |
| Study M666 | Type1 | late-life depression group vs. control group | Serum | Human | Down |
| Study M669 | Type1 | corticosterone group vs. control group | Liver | C57BL/6J mouse | Down |
| Study M684 | Type1 | LPS group vs. control group | Hippocampus | Wistar rat | Down |
| Study M690 | Type2 | CUMS + high dose of Zhi-zi-chi decoction group vs. CUMS group | Serum | Balb/c mouse | Down |
| Study M691 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M691 | Type2 | CUMS + low dose of Chaihu-Baishao group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M691 | Type2 | CUMS + low dose of Baishao group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M692 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M693 | Type1 | SDS group vs. control group | Plasma | C57BL/6J mouse | Down |
| Study M720 | Type1 | CUMS susceptible group vs. control group | Habenula | Sprague-Dawley rat | Down |
| Study M722 | Type1 | CUMS-transferred group vs. control-transferred group | Serum | C57BL/6J mouse | Down |
| Study M722 | Type1 | CUMS-transferred group vs. control-transferred group | Gut | C57BL/6J mouse | Down |
| Study M724 | Type1 | MDD group vs. control group | Serum | Human | Down |
| Study M728 | Type1 | CRS group vs. control group | Serum | C57BL/6 J mouse | Down |
| Study M732 | Type1 | CUMS + high dose of propionate group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Unknown |
| Study M732 | Type1 | CUMS + high dose of propionate group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M732 | Type2 | CUMS + middle dose of propionate group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M750 | Type2 | CUMS + CCFM1025 group vs. CUMS group | Faece | C57BL/6 mouse | Down |
| Study M760 | Type1 | CUMS group vs. control group | Hippocampus | Rat | Down |
| Study M766 | Type1 | CUS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M767 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M777 | Type1 | HFCS-MFD group vs. control group | Serum | C57Bl/6J mouse | Down |
| Study M779 | Type4 | responder group vs. non-responder group, at baseline | Plasma | Human | Up |
| Study M779 | Type4 | remitter group vs. non-remitter group, at baseline | Plasma | Human | Up |
| Study M787 | Type1 | CRS group vs. control group | Colon | Wistar rat | Up |
| Study M809 | Type1 | CUMS group vs. control group | Serum | Kunming mouse | Down |
| Study M810 | Type2 | post-rTMS treatment vs. baseline | Plasma | Human | Up |
| Study M814 | Type1 | CSDS group vs. control group | Serum | C57BL/6J mouse | Down |
| Study M823 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M828 | Type2 | ultrasonic radiation + intranasally clomipramine group vs. ultrasonic radiation group | Frontal cortex | Wistar rat | Down |
| Study M828 | Type2 | ultrasonic radiation + intraperitoneally clomipramine group vs. ultrasonic radiation group | Frontal cortex | Wistar rat | Down |
| Study M835 | Type1 | CRS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M839 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M844 | Type1 | CORT group vs. control group | PC12 cell | Rat | Up |
| Study M873 | Type1 | ovariectomy + CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M873 | Type2 | ovariectomy + CUMS + Xiang-Su volatile oil group vs. ovariectomy + CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M879 | Type1 | unipolar depression group vs. control group | Plasma | Human | Down |
| Study M882 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M884 | Type1 | CSDS group vs. control group | Ileum | C57BL/6J mouse | Up |
| Study M908 | Type3 | post-ketamine treatment vs. baseline | Cerebrospinal fluid | Human | Down |
| Study M913 | Type2 | responder group, post-escitalopram treatment vs. baseline | Plasma | Human | Up |
| Study M924 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M927 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M927 | Type2 | CUMS + Zhi-zi-chi decoction group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M928 | Type1 | CUMS group vs. control group | Prefrontal cortex | C57BL/6 mouse | Down |
| Study M942 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M942 | Type1 | CUMS group vs. control group | Serum | C57BL/6 mouse | Down |
| Study M942 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M942 | Type2 | CUMS + berberine group vs. CUMS group | Hippocampus | C57BL/6 mouse | Up |
| Study M942 | Type2 | CUMS + berberine group vs. CUMS group | Faece | C57BL/6 mouse | Up |
| Study M953 | Type1 | CRS group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M956 | Type1 | CUMS group vs. control group | Faece | C57BL/6J mouse | Down |
| Study M962 | Type2 | 24h-post ketamine infusion vs. baseline | Plasma | Human | Up |
| Study M969 | Type1 | CUMS group vs. control group | Hippocampus | ICR mouse | Up |
| Study M969 | Type2 | CUMS + Changyu Daotan Decoction group vs. CUMS group | Hippocampus | ICR mouse | Down |
| Study M976 | Type1 | small intestinal bacterial overgrowth group vs. control group | Urine | Human | Down |
| Study M976 | Type2 | small intestinal bacterial overgrowth group, after rifaximin treatment vs. baseline | Urine | Human | Up |
| Study M980 | Type1 | CMS group vs. control group | Olfactory bulb | C57BL/6J mouse | Down |
| Study M982 | Type1 | adult MDD group vs. adult control group | Plasma | Human | Down |
| Study M982 | Type2 | adult MDD group, post-treatment vs. baseline | Plasma | Human | Up |
| Study M983 | Type2 | adolescent MDD group, post-treatment vs. baseline | Plasma | Human | Down |
| Study M996 | Type1 | CUMS group vs. control group | Serum | C57BL/6J mouse | Down |